Zacks Investment Research upgraded shares of MOMENTA PHARMA (MNTA) from UNDERPERFORM to NEUTRAL on January 02, 2013, with a target price of $12.10.
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MOMENTA PHARMA (MNTA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment